How does tovorafenib stop cancer cells from growing?
Tovorafenib blocks a protein called RAF kinase, which cancer cells use to send 'grow' signals. By shutting off this signal, the drug slows or stops tumor growth. In the FIREFLY-1 trial, 67% of children with low-grade brain tumors showed tumor shrinkage or stable disease [1][2].
Tovorafenib is a type II RAF kinase inhibitor—a medicine that fits into a specific pocket on a cancer cell's growth-signal protein. In the FIREFLY-1 trial of 116 children with relapsed or refractory low-grade glioma, 67% achieved objective response (tumor shrinkage) or stable disease, with a median progression-free survival exceeding 24 months [1]. The drug works best in tumors that carry a BRAF genetic alteration, a common mutation in pediatric brain tumors.
Inside the cancer cell, RAF kinase normally sits at the top of a relay chain called the MAPK pathway—like the first domino in a line. When RAF is activated by a BRAF mutation, it triggers a cascade: RAF → MEK → ERK, and each step tells the cell to divide and grow. Tovorafenib wedges into RAF's active site and blocks this relay, starving the cancer cell of growth signals [5]. The drug reaches steady-state concentration in the bloodstream by day 7 of daily dosing.
In real-world practice, tovorafenib's benefit depends on three factors: (1) confirmed BRAF alteration on tumor genetic testing, (2) adequate liver and kidney function to clear the drug safely, and (3) tolerance of side effects like diarrhea and rash. Children who cannot tolerate the standard 100 mg dose can be reduced to 50 mg once daily with maintained efficacy [1]. Treatment typically continues until tumor progression or unacceptable toxicity, often 12–24+ months.
Before your child starts tovorafenib, ask the oncologist: 'Has the tumor been tested for BRAF alteration?' and 'What is the plan if my child develops severe diarrhea or rash?' Knowing the genetic result and the dose-adjustment protocol helps you feel prepared and confident.